USA - NASDAQ:QDEL - US2197981051 - Common Stock
The current stock price of QDEL is 26.99 USD. In the past month the price decreased by -9.97%. In the past year, price decreased by -30.97%.
|  Symbol  |  Company Name  |  TA  |  FA  |  PE  |  Market Cap  | 
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.77 | 215.16B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.05 | 191.53B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.14 | 149.24B | ||
| SYK | STRYKER CORP | 27.05 | 136.19B | ||
| MDT | MEDTRONIC PLC | 16.4 | 116.34B | ||
| BDX | BECTON DICKINSON AND CO | 12.52 | 51.22B | ||
| IDXX | IDEXX LABORATORIES INC | 52.42 | 50.36B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.08 | 48.41B | ||
| RMD | RESMED INC | 24.94 | 36.03B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.33 | 34.22B | ||
| DXCM | DEXCOM INC | 31.3 | 22.83B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.46 | 26.31B | 
 QuidelOrtho Corp. operates as a vitro diagnostics company. The company is headquartered in San Diego, California and currently employs 6,600 full-time employees.  The firm specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. The company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
QUIDELORTHO CORP
9975 Summers Ridge Road
San Diego CALIFORNIA 92121 US
CEO: Douglas C. Bryant
Employees: 6600
Phone: 18585521100
QuidelOrtho Corp. operates as a vitro diagnostics company. The company is headquartered in San Diego, California and currently employs 6,600 full-time employees. The firm specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. The company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
The current stock price of QDEL is 26.99 USD. The price increased by 0.67% in the last trading session.
QDEL does not pay a dividend.
QDEL has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
The PE ratio for QUIDELORTHO CORP (QDEL) is 11.53. This is based on the reported non-GAAP earnings per share of 2.34 and the current share price of 26.99 USD.
QUIDELORTHO CORP (QDEL) currently has 6600 employees.
QUIDELORTHO CORP (QDEL) will report earnings on 2025-11-06, after the market close.
ChartMill assigns a technical rating of 2 / 10 to QDEL. When comparing the yearly performance of all stocks, QDEL is a bad performer in the overall market: 77.99% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to QDEL. QDEL has a medium profitability rating, but doesn't score so well on its financial health evaluation.
Over the last trailing twelve months QDEL reported a non-GAAP Earnings per Share(EPS) of 2.34. The EPS decreased by -4.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.31% | ||
| ROE | -16.7% | ||
| Debt/Equity | 0.74 | 
14 analysts have analysed QDEL and the average price target is 42.16 USD. This implies a price increase of 56.21% is expected in the next year compared to the current price of 26.99.
For the next year, analysts expect an EPS growth of 22.53% and a revenue growth -2.61% for QDEL